Page 69 - 2021_09-Haematologica-web

Zanubrutinib in treatment naïve del(17p) CLL/SLL
tor, while one patient (0.9%) received at least one dose of an erythrocyte-stimulating growth factor. Of those patients with baseline anemia, 86.0% of patients demon- strated sustained improvement in hemoglobin; 75.0% of patients with baseline neutropenia also demonstrated sustained improvement in ANC, and 85.7% of patients
with baseline thrombocytopenia demonstrated sustained improvement in platelet count (Online Supplementary Table S3).
In an exploratory post hoc analysis, baseline characteris- tics and response rate were compared between patients with a percentage of del(17p)-positive nuclei of ≥20%
A
Figure 1. Survival and response analyses using the Kaplan-Meier method. (A) Progression-free survival as determined by investigator assessment. Shaded area indicates 95% Confidence Interval (CI). (B) Overall sur- vival. Shaded area indicates 95% CI. (C) Duration of response as determined by investigator assessment. Shaded area indicates 95% CI.
B
C
haematologica | 2021; 106(9)
2357